The Norwegian tenecteplase stroke trial (NOR-TEST): Randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Logallo, Nicola ^a,b   Kvistad, Christopher E ^a,b   Nacu, Aliona ^a,b   Naess, Halvor ^a,c   Waje Andreassen, Ulrike ^a,b   Asmuss, Jörg ^a   Aamodt, Anne H ^d   Lund, Christian ^d   Kurz, Martin W ^c   Rønning, Ole M ^e   Salvesen, Rolf ^f,g   Idicula, Titto T ^h   Thomassen, Lars ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^f NORDLAND HOSPITAL   (Norway)

^g UNIVERSITY OF TROMSØ   (Norway)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute ischaemic stroke; Alteplase; Intravenous thrombolysis; Tenecteplase

Indexed keywords

ALTEPLASE; TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ALBERTA STROKE PROGRAM EARLY CT SCORE; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPARATIVE STUDY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MECHANICAL THROMBECTOMY; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; OUTCOME ASSESSMENT; PERCUTANEOUS THROMBECTOMY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RECANALIZATION; SINGLE DRUG DOSE; STROKE UNIT; VASCULAR PATENCY; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; EMBOLECTOMY; ENDOVASCULAR SURGERY; MIDDLE AGED; MULTICENTER STUDY; NORWAY; PROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; EMBOLECTOMY; ENDOVASCULAR PROCEDURES; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901422822     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-106     Document Type: Article

References (29)

1. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, Levi CR. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009, 72(10):915-921. 10.1212/01.wnl.0000344168.05315.9d, 19273826.
2. NINDS: NINDS rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333(24):1581-1587. NINDS: NINDS rt-PA Stroke Study Group.
3. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009, 32(1):48-55. 10.1016/j.tins.2008.09.006, 18963068.
4. Parcq J, Bertrand T, Montagne A, Baron AF, Macrez R, Billard JM, Briens A, Hommet Y, Wu J, Yepes M, Lijnen HR, Dutar P, Angles-Cano E, Vivien D. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell death and differentiation 2012, 19(12):1983-1991. 10.1038/cdd.2012.86, 3504712, 22743997.
5. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nature medicine 2001, 7(1):59-64. 10.1038/83358, 11135617.
6. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator?. J Cereb Blood Flow Metab 2004, 24(9):945-963.
7. Haley EC, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010, 41(4):707-711. 10.1161/STROKEAHA.109.572040, 2860601, 20185783.
8. Meretoja A, Tatlisumak T. Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke?. CNS drugs 2008, 22(8):619-629. 10.2165/00023210-200822080-00001, 18601301.
9. Haley EC, Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005, 36(3):607-612. 10.1161/01.STR.0000154872.73240.e9, 15692126.
10. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, Zivin JA, Bennett WF. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994, 25(10):2072-2078. discussion 2078-2079, 10.1161/01.STR.25.10.2072, 8091454.
11. Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001, 32(3):748-752. 10.1161/01.STR.32.3.748, 11239197.
12. Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag 2009, 5(1):249-256. 2672445, 19436656.
13. Molina CA. TNK induces faster recanalization and leads to better short- and long-term clinical outcome than native tPA. The TNK-tPA reperfusion stroke study. Stroke 2008, 39:527. Abstract 141.
14. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Baterman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012, 366(12):1099-1107. 10.1056/NEJMoa1109842, 22435369.
15. Thomalla G, Cheng B, Ebinger M, Hao Q, Tourdias T, Wu O, Kim JS, Breuer L, Singer OC, Warach S, Christensen S, Treszl A, Forkert ND, Galinovic I, Rosenkranz M, Engelhorn T, Kohrmann M, Endres M, Kang DW, Dousset V, Sorensen AG, Liebeskind DS, Fiebach JB, Fiehler J, Gerloff C. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011, 10(11):978-986. 10.1016/S1474-4422(11)70192-2, 21978972.
16. Manawadu D, Bodla S, Keep J, Jarosz J, Kalra L. An observational study of thrombolysis outcomes in wake-up ischemic stroke patients. Stroke 2013, 44(2):427-431. 10.1161/STROKEAHA.112.673145, 23287781.
17. Hacke W, Donnan G, Fieschi C, Kaste M, Von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363(9411):768-774.
18. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369(9558):275-282. 10.1016/S0140-6736(07)60149-4, 17258667.
19. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010, 9(9):866-874. 10.1016/S1474-4422(10)70165-4, 20667790.
20. Nacu A. The Norwegian Sonothrombolysis in Acute Stroke Study (NOR-SASS). 2013, http://clinicaltrials.gov/show/NCT01949961.
21. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000, 355(9216):1670-1674.
22. Neumann-Haefelin T, Du Mesnil De Rochemont R, Fiebach JB, Gass A, Nolte C, Kucinski T, Rother J, Siebler M, Singer OC, Szabo K, Villringer A, Schellinger PD. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004, 35(1):109-114.
23. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359(13):1317-1329. 10.1056/NEJMoa0804656, 18815396.
24. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006, 77(7):826-829. 10.1136/jnnp.2005.086595, 2117477, 16505004.
25. Fjetland L, Roy S, Kurz KD, Larsen JP, Kurz MW. Endovascular acute stroke treatment performed by vascular interventional radiologists: is it safe and efficacious?. Cardiovasc Intervent Radiol 2012, 35(5):1029-1035. 10.1007/s00270-012-0438-5, 22752101.
26. Investigators IMSS. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004, 35(4):904-911.
27. Investigators IIT. The Interventional Management of Stroke (IMS) II Study. Stroke 2007, 38(7):2127-2135.
28. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013, 368(10):893-903. 10.1056/NEJMoa1214300, 3651875, 23390923.
29. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995, 92(10):3032-3040. 10.1161/01.CIR.92.10.3032, 7586274.